Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (58)
  • Open Access

    ARTICLE

    Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy

    Hsiang-Lin Tsai*†, Yen-Cheng Chen*‡, Tzu-Chieh Yin*§¶, Wei-Chih Su*‡, Po-Jung Chen*,Tsung-Kun Chang*†, Ching-Chun Li*, Ching-Wen Huang*†, Jaw-Yuan Wang*†‡#**††‡‡

    Oncology Research, Vol.29, No.1, pp. 47-61, 2021, DOI:10.3727/096504022X16451187313084

    Abstract Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in RAS wild-type metastatic colorectal cancer (mCRC) patients treated with cetuximab or bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation as the first-line therapy. In total, 173 patients with mCRC with RAS wild-type were enrolled. Among them, 98 patients were treated with cetuximab, whereas 75 patients were treated with bevacizumab. All patients received irinotecan dose escalation based on UGT1A1 genotyping. We compared the progression-free survival (PFS),… More >

  • Open Access

    ARTICLE

    Real-World Data: Fruquintinib in Treating Metastatic Colorectal Cancer

    Shuai Liu*†1, Lu Lu*†1, Feng Pan, Chunsheng Yang*†, Jing Liang§, Jinfeng Liu, Jian Wang#, Rong Shen**, Fu-Ze Xin††, Nan Zhang*†

    Oncology Research, Vol.29, No.1, pp. 25-31, 2021, DOI:10.3727/096504022X16427607626672

    Abstract Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival (PFS) was evaluated using the… More >

  • Open Access

    ARTICLE

    Knockdown Wiskott-Aldrich syndrome protein family member 3 (WASF3) inhibits colorectal cancer metastasis and sensitizes to cisplatin through targeting ZNF471

    ZHIYONG ZHANG1,#, YAN PAN2,#, YAN ZHAO1, MUDAN REN1, YARUI LI1, YUN FENG1, GUIFANG LU1,*, SHUIXIANG HE1,*

    BIOCELL, Vol.46, No.8, pp. 1917-1924, 2022, DOI:10.32604/biocell.2022.018847

    Abstract Colorectal cancer (CRC) is a heterogeneous cancer, and many risk factors for colorectal cancer have been established. For CRC metastasis, tumor cell migration, adhesion as well as invasion are important processes. WiskottAldrich syndrome protein family member 3 (WASF3) is necessary for metastasis of various types of cancers. However, its role in CRC progression has not been fully elucidated. This study examined the in vitro functional roles of WASF3 in the CRC and explored the underlying molecular mechanisms. We used siRNA-WASF3 to gene silence WASF3 in colon cancer cell (HCT116) in vitro. The effects of WASF3 silencing on HCT116 cell apoptosis,… More >

  • Open Access

    ARTICLE

    Automated Artificial Intelligence Empowered Colorectal Cancer Detection and Classification Model

    Mahmoud Ragab1,2,3,*, Ashwag Albukhari2,4

    CMC-Computers, Materials & Continua, Vol.72, No.3, pp. 5577-5591, 2022, DOI:10.32604/cmc.2022.026715

    Abstract Colorectal cancer is one of the most commonly diagnosed cancers and it develops in the colon region of large intestine. The histopathologist generally investigates the colon biopsy at the time of colonoscopy or surgery. Early detection of colorectal cancer is helpful to maintain the concept of accumulating cancer cells. In medical practices, histopathological investigation of tissue specimens generally takes place in a conventional way, whereas automated tools that use Artificial Intelligence (AI) techniques can produce effective results in disease detection performance. In this background, the current study presents an Automated AI-empowered Colorectal Cancer Detection and Classification (AAI-CCDC) technique. The proposed… More >

  • Open Access

    ARTICLE

    Optimized Deep Learning Model for Colorectal Cancer Detection and Classification Model

    Mahmoud Ragab1,2,3,*, Khalid Eljaaly4, Maha Farouk S. Sabir5, Ehab Bahaudien Ashary6, S. M. Abo-Dahab7,8, E. M. Khalil3,9

    CMC-Computers, Materials & Continua, Vol.71, No.3, pp. 5751-5764, 2022, DOI:10.32604/cmc.2022.024658

    Abstract The recent developments in biological and information technologies have resulted in the generation of massive quantities of data it speeds up the process of knowledge discovery from biological systems. Due to the advancements of medical imaging in healthcare decision making, significant attention has been paid by the computer vision and deep learning (DL) models. At the same time, the detection and classification of colorectal cancer (CC) become essential to reduce the severity of the disease at an earlier stage. The existing methods are commonly based on the combination of textual features to examine the classifier results or machine learning (ML)… More >

  • Open Access

    ARTICLE

    Calcium supplementation in colorectal cancer prevention: A systematic meta-analysis of adverse events

    XUE MEI LUO1, SHAHANAVAJ KHAN2,3,4,*, ABDUL MALIK2, FAHAD M. ALDAKHEEL5, ANIS AHMAD CHAUDHARY6, SHOUKI BAZARBASHI7, FATEMEH TABATABAIE8

    BIOCELL, Vol.46, No.3, pp. 759-767, 2022, DOI:10.32604/biocell.2022.016586

    Abstract Despite the multiple systematic reviews and meta-analyses accumulating evidence on the preventive effect of calcium supplementation for colorectal cancer, most of the associated adverse effects are not systematically analyzed. The aim of the study is evaluating adverse events associated with calcium supplementation for colorectal cancer prevention through a systematic meta-analysis. We searched Medline, PubMed Central, EMBASE (Excerpta Medica database), Scopus, Cochrane Central Register of Controlled Trials, and Web of Science published in English from database inception up to 31 July 2019. In the current systematic meta-analysis, we included human studies (including cohort studies, clinical trials, case-control studies) on supplementation of… More >

  • Open Access

    ARTICLE

    Lysophosphatidylcholine acyltransferase 1 is involved in the regulation of exosome secretion and uptake in colorectal cancer cells

    HAIZHENG LIU1, SHAOFEI CHANG2,*

    BIOCELL, Vol.46, No.2, pp. 453-462, 2022, DOI:10.32604/biocell.2021.015340

    Abstract Lysophosphatidylcholine acyltransferase 1 (LPCAT1) is a phospholipid acyltransferase that promotes phospholipid synthesis and plasma membrane reconstruction. Exosomes play an important role in tumor metastasis. The release and uptake of exosomes are key steps of their functions and depend on plasma membrane fusion and plasma membrane receptors, respectively. The purpose of this study was to explore whether LPCAT1-induced plasma membrane remodeling would change the secretion and uptake behavior of exosomes in tumor cells. We first confirmed the abnormally high expression of LPCAT1 in colorectal cancer cells by quantitative real-time PCR (qPCR) and Western blot analysis. Then, SW620 cells were used as… More >

  • Open Access

    ARTICLE

    Elp3 modulates neural crest and colorectal cancer migration requiring functional integrity of HAT and SAM domains

    XIANGCAI YANG1,2,*, YA XU3, SHUTING MEI1, JIEJING LI3,*

    BIOCELL, Vol.46, No.2, pp. 463-470, 2022, DOI:10.32604/biocell.2021.014834

    Abstract Cell migration is a finely tuned biological process that often involves epithelial-mesenchymal transition (EMT). EMT is typically characterized by the upregulation of mesenchymal markers such as Snail1. This process has been shown to be of critical importance to normal developmental processes, including neural crest migration and invasion. Interestingly, similar mechanisms are utilized in disease processes, such as tumor metastasis and migration. Notably, EMT and EMT-like processes confer tumor cells with the ability to migrate, invade, and adopt stem cell-like properties that largely account for immunosuppression and tumor recurrence. Therefore, identifying sensitive EMT markers may contribute to cancer prognosis and diagnosis… More >

  • Open Access

    REVIEW

    Metformin and colorectal cancer

    GASTÓN AMABLE#, EDUARDO MARTÍNEZ-LEÓN#, MARÍA E. PICCO, OSVALDO REY

    BIOCELL, Vol.46, No.1, pp. 51-59, 2022, DOI:10.32604/biocell.2022.017565

    Abstract Colorectal cancer (CRC) is one of the main causes of cancer-related mortality in the developed world despite recent developments in detection and treatment. Several epidemiological studies indicate that metformin, a widely prescribed antidiabetic drug, exerts a protective effect on different cancers including CRC. Furthermore, a recent double-blind placebo-controlled, randomized trial showed that metformin significantly decreased colorectal adenoma recurrence. Studies exploring the mechanism of action of metformin in cells derived from different types of cancers reported many effects including respiratory chain complex 1 inhibition, Akt phosphorylation inhibition, ATP depletion, PKA activation and Wnt signaling inhibition. However, many of these results were… More >

  • Open Access

    ARTICLE

    Exendin-4 inhibits the survival and invasiveness of two colorectal cancer cell lines via suppressing GS3Kβ/β-catenin/NF-κB axis through activating SIRT1

    ATTALLA F. EL-KOTT1,2,*, AYMAN E. EL-KENAWY3, EMAN R. ELBEALY4, ALI S. ALSHEHRI1, HEBA S. KHALIFA2, MASHAEL MOHAMMED BIN-MEFERIJ5, EHAB E. MASSOUD6,7,8, AMIRA M. ALRAMLAWY9

    BIOCELL, Vol.45, No.5, pp. 1337-1353, 2021, DOI:10.32604/biocell.2021.015464

    Abstract This study examined if the anti-tumorigenesis effect of Exendin-4 in HT29 and HCT116 colorectal cancer (CRC) involves modulation of SIRT1 and Akt/GSR3K/β-catenin/NF-κB axis. HT29 and HCT116 cells were treated either with increasing levels of Exendin-4 (0.0-200 µM) or with Exendin-4 (at its IC50) in the presence or absence of EX-527 (10 µM/a selective SIRT1 inhibitor) or Exendin-4 (9-39) amide (E (9-39) A) (1 µM/an Exendin-4 antagonist). In a dose-dependent manner, Exendin-4 inhibited cell survival, but enhanced levels of lactate dehydrogenase (LDH) and single-stranded DNA (ssDNA) in both HT29 and HCT116. In both cell lines and at it has an IC50More >

Displaying 41-50 on page 5 of 58. Per Page